{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:01:26Z","timestamp":1788735686827,"version":"build-2803163510"},"reference-count":44,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2018,5,11]]},"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>Supplementation with B vitamins (vitamin B<jats:sub>9<\/jats:sub>(folic acid), vitamin B<jats:sub>12<\/jats:sub> and vitamin B<jats:sub>6<\/jats:sub>) lowers blood total homocysteine (tHcy) concentrations by about 25% and reduces the relative risk of stroke overall by about 10% (risk ratio (RR) 0.90, 95% CI 0.82 to 0.99) compared with placebo. Homocysteine-lowering interventions have no significant effect on myocardial infarction, death from any cause or adverse outcomes. Factors that appear to modify the effect of B vitamins on stroke risk include low folic acid status, high tHcy, high cyanocobalamin dose in patients with impaired renal function and concurrent antiplatelet therapy. In regions with increasing levels or established policies of population folate supplementation, evidence from observational genetic epidemiological studies and randomised controlled clinical trials is concordant in suggesting an absence of benefit from lowering of homocysteine with folic acid for prevention of stroke. Clinical trials indicate that in countries which mandate folic acid fortification of food, folic acid supplementation has no significant effect on reducing stroke risk (RR 1.05, 95% CI 0.90 to 1.23). However, in countries without mandatory folic acid food fortification, folic acid supplementation reduces the risk of stroke by about 15% (RR 0.85, 95% CI 0.77 to 0.94). Folic acid alone or in combination with minimal cyanocobalamin (\u22640.05 mg\/day) is associated with an even greater reduction in risk of future stroke by 25% (RR 0.75, 95% CI 0.66 to 0.86), whereas the combination of folic acid and a higher dose of cyanocobalamin (\u22650.4 mg\/day) is not associated with a reduced risk of future stroke (RR 0.95, 95% CI 0.86 to 1.05). The lack of benefit of folic acid plus higher doses of cyanocobalamin (\u22650.4 mg\/day) was observed in trials which all included participants with chronic kidney disease. Because metabolic B<jats:sub>12<\/jats:sub> deficiency is very common and usually not diagnosed, future randomised trials of homocysteine-lowering interventions for stroke prevention should probably test a combination of folic acid and methylcobalamin or hydroxocobalamin instead of cyanocobalamin, and perhaps vitamin B<jats:sub>6<\/jats:sub>.<\/jats:p>","DOI":"10.1136\/svn-2018-000156","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T02:05:32Z","timestamp":1528337132000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":48,"title":["B vitamins for stroke prevention"],"prefix":"10.1136","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-7328","authenticated-orcid":false,"given":"Graeme J","family":"Hankey","sequence":"first","affiliation":[{"name":"UWA Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Department of Neurology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"2025081709360159000_3.2.51.1","first-page":"111","article-title":"Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis","volume":"56","author":"McCully","year":"1969","journal-title":"Am J Pathol"},{"key":"2025081709360159000_3.2.51.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198509193131201"},{"key":"2025081709360159000_3.2.51.3","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005373209964"},{"key":"2025081709360159000_3.2.51.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104253241701"},{"key":"2025081709360159000_3.2.51.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540460039030"},{"key":"2025081709360159000_3.2.51.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.16.2015"},{"key":"2025081709360159000_3.2.51.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7374.1202"},{"key":"2025081709360159000_3.2.51.8","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.12.2922"},{"key":"2025081709360159000_3.2.51.9","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000115161.10646.67"},{"key":"2025081709360159000_3.2.51.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.866889"},{"key":"2025081709360159000_3.2.51.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7135.894"},{"key":"2025081709360159000_3.2.51.12","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1474-4422(17)30180-1","article-title":"B vitamins in stroke prevention: time to reconsider","volume":"16","author":"Spence","year":"2017","journal-title":"Lancet Neurol"},{"key":"2025081709360159000_3.2.51.13","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.7.1704"},{"key":"2025081709360159000_3.2.51.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2004.00250.x"},{"key":"2025081709360159000_3.2.51.15","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-872394"},{"key":"2025081709360159000_3.2.51.16","first-page":"414","article-title":"Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase","volume":"43","author":"Kang","year":"1988","journal-title":"Am J Hum Genet"},{"key":"2025081709360159000_3.2.51.17","doi-asserted-by":"publisher","DOI":"10.1038\/ng0595-111"},{"key":"2025081709360159000_3.2.51.18","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.23.2520"},{"key":"2025081709360159000_3.2.51.19","first-page":"1\u00ad31","article-title":"The natural history of homocystinuria due to cystathionine beta-synthase deficiency","volume":"37","author":"Mudd","year":"1985","journal-title":"Am J Hum Genet"},{"key":"2025081709360159000_3.2.51.20","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"2025081709360159000_3.2.51.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17742-3"},{"key":"2025081709360159000_3.2.51.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60872-6"},{"key":"2025081709360159000_3.2.51.23","first-page":"CD006612","article-title":"Homocysteine-lowering interventions for preventing cardiovascular events","volume":"8","author":"Mart\u00ed-Carvajal","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025081709360159000_3.2.51.24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003768"},{"key":"2025081709360159000_3.2.51.25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.amjms.2017.05.020","article-title":"Folic acid supplementation for stroke prevention in patients with cardiovascular disease","volume":"354","author":"Tian","year":"2017","journal-title":"Am J Med Sci"},{"key":"2025081709360159000_3.2.51.26","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1212\/WNL.0000000000003909","article-title":"Meta-analysis of folic acid efficacy trials in stroke prevention: Insight into effect modifiers","volume":"88","author":"Zhao","year":"2017","journal-title":"Neurology"},{"key":"2025081709360159000_3.2.51.27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5853\/jos.2017.01522","article-title":"Folic acid in stroke prevention in countries without mandatory folic acid food fortification: a meta-analysis of randomized controlled trials","volume":"20","author":"Hsu","year":"2018","journal-title":"J Stroke"},{"key":"2025081709360159000_3.2.51.28","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1212\/WNL.0000000000004648","article-title":"Association between percent decline in serum total homocysteine and risk of first stroke","volume":"89","author":"Huang","year":"2017","journal-title":"Neurology"},{"key":"2025081709360159000_3.2.51.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1113996"},{"key":"2025081709360159000_3.2.51.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutres.2015.10.003"},{"key":"2025081709360159000_3.2.51.31","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.310211"},{"key":"2025081709360159000_3.2.51.32","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000185929.38534.f3"},{"key":"2025081709360159000_3.2.51.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70187-3"},{"key":"2025081709360159000_3.2.51.34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.490"},{"key":"2025081709360159000_3.2.51.35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jamainternmed.2016.4687","article-title":"Efficacy of folic acid therapy on the progression of chronic kidney disease: the renal substudy of the china stroke primary prevention trial","volume":"176","author":"Xu","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025081709360159000_3.2.51.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055227"},{"key":"2025081709360159000_3.2.51.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060900"},{"key":"2025081709360159000_3.2.51.38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c6273"},{"key":"2025081709360159000_3.2.51.39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.840"},{"key":"2025081709360159000_3.2.51.40","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.12.035"},{"key":"2025081709360159000_3.2.51.41","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.018273"},{"key":"2025081709360159000_3.2.51.42","doi-asserted-by":"publisher","DOI":"10.1177\/1747493015616512"},{"key":"2025081709360159000_3.2.51.43","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1056\/NEJMcp1503946","article-title":"Cryptogenic Stroke","volume":"374","author":"Saver","year":"2016","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025081709360159000_3.2.51.44","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis","volume":"319","author":"Navarese","year":"2018","journal-title":"JAMA"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2018-000156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:36:08Z","timestamp":1755448568000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2018-000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6,26]]},"published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1136\/svn-2018-000156"],"URL":"https:\/\/doi.org\/10.1136\/svn-2018-000156","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}